Education
About Us
Working with TipRanks
Follow Us
Isofol Medical AB (SE:ISOFOL)
:ISOFOL
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr2.14
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr165.43M
Enterprise Valuekr122.60M
Total Cash (Recent Filing)kr138.79M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,107,240
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt across 2023–2025 gives durable financial resilience for a pre-commercial biotech. Low leverage reduces interest burden and bankruptcy risk, allowing management to prioritize R&D and partnering timing over debt servicing during multi-year clinical programs.
Improved Cash BurnMaterial reduction in operating cash outflows versus earlier years reflects tighter cost control and greater capital efficiency. A sustainably lower burn rate lengthens runway, lowers frequency/size of financing needs, and makes achieving key clinical/regulatory milestones more likely without immediate large dilutions.
Focused R&D & Partnering StrategyConcentrating on development and partnering for lead asset arfolitixorin aligns resources toward proof‑of‑concept and regulatory value-creation rather than costly commercialization buildout. This capital-light strategy is durable, enabling leverage of partners' commercial scale if clinical success is achieved.
Bears Say
No Sustained RevenueA return to zero product revenue confirms a fully pre-commercial profile; without sales the company must rely on capital markets or partners for funding. This structural lack of revenue increases execution risk and means clinical success is required to shift to self-sustaining cash flows.
Persistent Negative Cash FlowDespite improvement, ongoing negative operating cash flow means the business continues to consume capital annually. Persistently negative cash generation forces repeated external financing or asset monetization, raising dilution risk and constraining long-term strategic optionality if clinical timelines slip.
Equity Erosion / Funding RiskMaterial decline in equity over several years reduces the balance-sheet buffer and signals significant accumulated losses and financing activity. A thinner equity base makes the company more sensitive to adverse trial outcomes and increases the likelihood of future dilutive financings to sustain development.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr2.14 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr165.43M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 85 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 281,107,240 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―